By integrating single-cell data and bulk-RNA sequencing data, this study aims to construct a prognostic immune signature (PIS), which can accurately predict the progression-free survival (PFS) of patients with ccRCC with anti-PD-1 therapy. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.